Summary LM985 has been shown previously to hydrolyse to flavone acetic acid (LM975) in mouse plasma and to produce significant anti-tumour effects in transplantable mouse colon tumours (MAC). It 4H-1 -benzopyran-8-acetic acid, 4 oxo-2-phenyl-,2-(diethylamino) ethylester hydrochloride ( Figure IA) The development of several adenocarcinomata of the large bowel in NMRI mice from primary tumours induced by prolonged administration of 1,2-dimethylhydrazine has been described elsewhere 
Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid) 4H-1 -benzopyran-8-acetic acid, 4 oxo-2-phenyl-,2-(diethylamino) ethylester hydrochloride ( Figure IA ) was selected for Phase I clinical evaluation largely on its activity against colon 38 in the NCI screen. Double et al. (1986) have demonstrated significant activity against mouse transplantable subcutaneous colon tumours (MAC) and also confirmed the rapid hydrolysis of LM985 to flavone acetic acid (LM975) ( Figure 1B ) suggested by Kerr et al. (1985 The development of several adenocarcinomata of the large bowel in NMRI mice from primary tumours induced by prolonged administration of 1,2-dimethylhydrazine has been described elsewhere 
Chemosensitivity
In vivo studies The anti-tumour activity of LM985 against MAC 13, MAC 26 and MAC 15A has been described previously (Double et al., 1986) . The activity of LM975 against these tumours was assessed by using the same protocols. Chemotherapy commenced 2 days after implantation for MAC 13 and MAC 15A tumour bearers and 21 days after implantation for MAC 26 tumour bearers. MAC 13 tumours were assessed 14 days later by recording tumour weights and MAC 15A tumours were assessed from median survival times (Geran et al., 1972) . MAC 26 tumours were assessed by twice weekly two-dimensional caliper measurements. Activity scores for LM975 and positive control compounds against each tumour line, were allocated by the method of Double et al., (1986) .
In vitro studies Treatment effects of the drugs were assessed using a clonogenic assay (Hamburger & Salmon, 1977 
Results
In vivo anti-tumour activity of LM975 The i.p. maximum tolerated dose of LM975 in NMRI mice was 300 mg kg-1. The compound had no effect against MAC 15A ascites tumours (Table I) . Single dose treatment against MAC 13 produces some tumour inhibition but this is considerably enhanced by repeat treatment (Table II) .
Greater than 90% tumour inhibition can be achieved at 300 mg kg-1 on day 2 and day 9 with no indication of toxicity. Similar responses are seen with the slower growing MAC 26 tumours with cures being achieved with 300mg kg-1 on day 0 and day 7 (Figure 2 ).
In vitro chemosensitivity MAC 13 cells grown in vitro are sensitive to LM985 but MAC 15A cells are much less responsive (Figure 3 ). In vitro chemosensitivity data of MAC 13 cells to LM975 are presented in Figure 4 . Two hour exposure to doses of up to 2mgml-1 of LM975 fail to produce a response in MAC 15A cells ( Figure 5 ). Longer exposure times result in signifi- Peritoneal levels of LM985 and LM975 following i.p. inoculation of 3 dose levels of LM985 are presented in Figure 7 . Both LM985 and LM975 are rapidly cleared from the peritoneum. Levels of LM975 in the peritoneum and plasma following i.p. inoculation of three dose levels are described in Figure 8 . Identical curves were produced when these measurements were repeated 7 days later. Kerr et al. (1986) have completed a Phase I clinical trial with LM985 and are currently conducting a similar trial with LM975. They state that higher doses of LM975 can be given without dose limiting toxicity and probably without loss of anti-tumour activity. The in vivo responses achieved here with MAC 13 and MAC 26 confirm LM975 to be highly active against s.c. mouse tumours. The lack of response of the ascites tumour MAC 15A to LM975 in vivo is more interesting as analysis of LM975 in the peritoneum following i.p. administration reveals high levels for the first 30 min.
In vitro chemosensitivity studies show that MAC 15A cells are in fact less responsive to LM975 than LM985. They are unresponsive to 2 h exposures of concentration of up to 2mg ml-1 but long term exposures result in improved cytotoxicity. The concentrations and exposure times experienced by MAC 15A tumours grown in vivo are therefore insufficient to produce a response. Comparison of in vitro assays with LM975 and LM985 indicate the parent compound to be considerably more active against MAC 13 than the hydrolysis product. Long term exposures to LM975 in vitro result in improved cytotoxicity.
In conclusion this study reveals that LM975 is less active in vitro than LM985 but that in vitro chemosensitivity to LM975 increases with prolonged exposures. Dose response curves show the minimum drug concentrations and exposure times required to effect a response in vitro and would suggest that if these parameters are achievable in vivo the tumour would respond. Pharmacokinetic studies have indicated the plasma levels necessary to achieve a response in subcutaneous tumours, and these levels are lower than those predicted in the MAC 13 in vitro assays. Protein binding studies of LM975 in mouse and human plasma have indicated moderate binding. The reasons for the apparent difference in chemosensitivity between in vitro and in vivo tumours are under investigation.
From Table II the more than additive percentage cell kill produced by the second injection is difficult to explain, as this phenomenon has never been observed with standard agents in this tumour system. The cures seen in MAC 26 have never previously been achieved. The measurement of pharmacokinetic parameters provide no explanation for the dramatic tumour responses achieved by repeated treatment as these were identical for mice treated at days 2 and 9. This phenomenon will be the subject of further investigation.
The MAC series of tumours has previously been shown to be a good model of human disease with responses to standard agents only seen close to maximum tolerated dose . Similar anti-tumour responses may well be achieved in human large bowel cancer if the minimum drug concentrations and exposure times presented here can be achieved in man. 
